NASDAQ: MGX

Metagenomi Inc Stock Forecast, Predictions & Price Target

The consensus among 5 Wall Street analysts covering (NASDAQ: MGX) stock is to Strong Buy MGX stock.

Out of 5 analysts, 4 (80%) are recommending MGX as a Strong Buy, 1 (20%) are recommending MGX as a Buy, 0 (0%) are recommending MGX as a Hold, 0 (0%) are recommending MGX as a Sell, and 0 (0%) are recommending MGX as a Strong Sell.

If you're new to stock investing, here's how to buy Metagenomi stock.

(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of 6.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.94%.

Metagenomi's revenue in 2024 is $44,756,000.On average, 3 Wall Street analysts forecast MGX's revenue for 2024 to be $1,426,572,403, with the lowest MGX revenue forecast at $1,049,225,828, and the highest MGX revenue forecast at $1,761,200,497. On average, 3 Wall Street analysts forecast MGX's revenue for 2025 to be $1,947,438,081, with the lowest MGX revenue forecast at $1,356,873,830, and the highest MGX revenue forecast at $2,503,153,047.

In 2026, MGX is forecast to generate $1,773,941,096 in revenue, with the lowest revenue forecast at $1,773,941,096 and the highest revenue forecast at $1,773,941,096.

According to 5 Wall Street analysts that have issued a 1 year MGX price target, the average MGX price target is $21.40, with the highest MGX stock price forecast at $25.00 and the lowest MGX stock price forecast at $16.00.

On average, Wall Street analysts predict that Metagenomi's share price could reach $21.40 by Mar 28, 2025. The average Metagenomi stock price prediction forecasts a potential upside of 184.2% from the current MGX share price of $7.53.

(NASDAQ: MGX) forecast ROE is N/A, which is considered weak.